osimertinib
astrazeneca
['osimertinib']
if the control arm patients do not get osimertinib, it becomes a trial of osimertinib ever versus osimertinib never. not a trial of whether osimertinib is needed as adjuvant versus as 1l at the time of relapse. #asco23 
Personal account. Med Onc. Associate Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO